Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma
Authors:
- Diana D. ShiDSDiana D. Shi
- Ester Calvo FernándezEFEster Calvo Fernández
- Vinesh T. PuliyappadambaVPVinesh T. Puliyappadamba
- Tyler A. LanmanTLTyler A. Lanman
- Yi XiaoYXYi Xiao
- Zebin WenZWZebin Wen
- Maria MinorMMMaria Minor
- Diego ProstDPDiego Prost
- Aleksandra B. LasicaALAleksandra B. Lasica
- Feng CaiFCFeng Cai
- Ethan NeumannENEthan Neumann
- Sriram GudipellySGSriram Gudipelly
- 5 August 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (861)
Abstract
The mutant isocitrate dehydrogenase 1/2 inhibitor (mIDHi) vorasidenib was recently incorporated into clinical treatment guidelines for IDH-mutant gliomas, although its impact on chemoradiation is unclear. Specifically, it is unknown whether upfront mIDHi exposure alters subsequent chemoradiation efficacy. Addressing this critical question has been challenging because of limited clinical data and a paucity of mIDHi-responsive preclinical glioma models. We first established that a genetic mouse model of IDH-mutant astrocytoma developed by our group was responsive to vorasidenib monotherapy. We then used this mouse to address whether mIDHi alters the response to chemoradiation after progression on mIDHi. Mice that received upfront vorasidenib followed by chemoradiation at progression had improved survival compared with control mice receiving vehicle followed by chemoradiation. We then compiled real-world data and early outcomes from 29 patients who were among the first to receive mIDHi followed by radiation with or without chemotherapy. Our study directly addresses uncertainty surrounding therapy sequencing that has emerged after introduction of vorasidenib as a first-line treatment for IDH-mutant glioma. Our empirical preclinical data demonstrate that prior mIDHi treatment enhances chemoradiation sensitivity of IDH-mutant glioma.Keywords
Funding Information
- National Institutes of Health (R01CA258586)
- National Institutes of Health (R01CA289260)
- National Institutes of Health (R01NS142141)
- National Institutes of Health (P50CA165962)
- National Institutes of Health (U19CA264504)
- National Institutes of Health (R35CA220449)
- National Institutes of Health (R01CA276765)
- National Institutes of Health (R35CA210068)
- National Institutes of Health (NIH/NCI K12CA0903354)
- National Institutes of Health (NIH/NCI K08CA283279-01A1)
- National Institutes of Health (NIH 1DP5OD039431-01)
- Cancer Prevention and Research Institute of Texas (RR190034)
- Cancer Prevention and Research Institute of Texas (RP230344)
- Cancer Prevention and Research Institute of Texas (RP240489)
- National Institutes of Health (NIH 5T32CA009216-45)
- National Institutes of Health (RP210099)
- Cancer Prevention and Research Institute of Texas (RP240494)
- Institut du Cerveau et de la Moelle Epinière (PAIR TUMC21-001)
- Fondation ARC pour la Recherche sur le Cancer (18010)
- Cancer Prevention and Research Institute of Texas (RP240494)
- National Institutes of Health (2P50CA165962-11)
- National Institutes of Health (1U54CA274516-01A1)
- National Institutes of Health (1R01CA284565-01A1)
- National Institutes of Health (K99CA277576)
- Human Frontier Science Program (LT0018/2022-L)
- Burroughs Wellcome Fund
- Lubin Family Foundation Scholar Award
- National Institutes of Health (R01GM158820)
- Cancer Prevention and Research Institute of Texas (RP260474)
This publication has 34 references indexed in Scilit:
- Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaCancer Cell, 2024
- Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytomaSTAR Protocols, 2023
- De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant gliomaCancer Cell, 2022
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- Mutant IDH1 Promotes Glioma Formation In VivoCell Reports, 2018
- CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer ModelingCell, 2014
- IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigeneticsNature, 2012
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Application of a flow cytometric method using autofluorescence and a tandem fluorescent dye to analyze human alveolar macrophage surface markersJournal of Immunological Methods, 1994